Foundation Medicine prices IPO; SeraCare bumps up diagnostics manufacturing capacity;

> Massachusetts diagnostics darling Foundation Medicine priced its IPO at about $106 million, selling more than 5.8 million shares of common stock at $18 each, well above its initial projections. Item

> Veracyte, a molecular diagnostics company, has filed plans for a proposed IPO that could reach nearly $75 million. Story

> Cancer diagnostics maker Biocept Laboratories is mulling an IPO worth up to $23 million. Story

> The EpimiRNA Consortium is getting €11.5 million ($15.5 million) in funding from the European Union to investigate molecular mechanisms, diagnostics and treatments for epilepsy. Item

> Forsite Diagnostics in the U.K. won a European Commission grant to develop a rapid molecular diagnostic test for malaria. Item

> Paraguayan and Uruguayan scientists are developing an inexpensive diagnostic for syphilis that they hope to launch by early 2014. Item

> SeraCare Life Sciences is expanding research and manufacturing capacity at its Milford, MA, headquarters so it can handle increased diagnostic manufacturing demand from its major partners. Story

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.